• Mass General Brigham Ventures

Big Day for Four Biopharmas Who Net Millions in Add-on Funds

Several biopharma companies announced Series B financing rounds or additional investment raises. Here’s a look.


Vanqua Bio Closes $85 Million Series B to Focus on Neurodegenerative Diseases

Chicago-based Vanqua Bio closed on an $85 million Series B financing round. It was led by Omega Funds and included Series A investor OrbiMed and new investors Omega Funds, Surveyor Capital, Avoro Ventures, Casdin Capital, Pontifax, Eli Lilly and Company, Logos Capital, and Osage University Partners.


The company focuses on neurodegenerative diseases. Its lead program is developing small-molecule activators of glucocerebrosidase (GCase). This enzyme regulates lipid homeostasis in cells. Decreases in GCase activity disrupt lysosome function, allowing for the buildup of toxic proteins, including alpha synuclein, which is found in several neurodegenerative diseases, including Parkinson’s disease.


“Of the eight million Parkinson’s patients around the world, up to 800,000 have GBA-PD,” said Jonathan Silverstein, member of Vanqua’s board of directors, Executive Partner at OrbiMed, and founder of the Silverstein Foundation for Parkinson’s with GBA. “Vanqua Bio’s unique approach to discovering novel GCase activators holds great promise in enabling new targeted therapies for GBA-PD patients.”


ROME Therapeutics Pulls in $77 Million in Series B For Repeatomics Platform

Cambridge, Mass.-based ROME Therapeutics completed a $77 million Series B financing. The round was led by new investor Section 32 and included new investors Sanofi Ventures, Casdin Capital, Andreessen Horowitz and Alexandria Venture Investments. Existing investors ARCH Ventures, GV and Mass General Brigham Ventures also participated. As part of the round, Steven J. Kafka, Managing Partner at Section 32, and Jim Trenkle, Head of Investments at Sanofi Ventures, are joining the company’s board of directors.

The company is focused on the so-called “repeatome.” Approximately 60% of the human genome is made up of repeating sequences of nucleic acids, called repeats. Recent research has shown that these repeats have implications for cancer, autoimmune disease and other clinical areas.


“In the short time since our founding, ROME has made significant progress uncovering the role and mechanism of the repeatome in cancer and autoimmune diseases, which has led to our foundational repeatomics platform and identification of multiple tractable targets for drug discovery,” said Rosana Kapeller, President, Chief Executive Officer and CO-Founder of ROME.


TreeFrog Raises $75 Million in Series B to Advance Cell Therapies

TreeFrog Therapeutics, based in Bourdeaux, France, closed on a Series B financing round worth $75 million. The round was led by Bpifrance Large Venture, part of the French Public Investment Bank. It was joined by U.S. firm Leonard Green & Partners, Bristol Myers Squibb, and European venture capital team XAnge.


Independent board member Frederic Desddouits has been appointed Chief Executive Officer. Kevin Alessandri, co-founder, will move in early 2022 to Boston to lead the newly created U.S. subsidiary, Treefrog Therapeutics. Laurent Higuerot, with Bpifrance, and Peter Zippelius, of Leonard Green, will join the board. Girish Pendse, of BMS, will join the board as an observer. The chairman of the board will be co-founder Jean-Luc Treillou.

The company is planning to develop cell therapies by way of C-Stem, a high-throughput cell encapsulation technology platform. This allows for the mass production and differentiation of stem cells in industrial bioreactors.


Skyhawk Therapeutics Raises $133 Million in Recent Oversubscribed Investment Round

Waltham, Mass.-based Skyhawk Therapeutics indicated that Fidelity Management & Research Company LLC led a $133 million oversubscribed investment round in the company. It included other unnamed investors. The round brings the total funding in the company to more than $600 million.


The company focuses on RNA mis-expression. Their compounds modify expression of target genes that were previously considered undruggable for a wide range of indications, including cancer, neurodegenerative disease, autoimmune, inflammatory, and infectious diseases. Their technology platform is SkySTAR, which stands for Skyhawk Small molecule Therapeutics for Alternative splicing in RNA. It leverages an integration of data from computational, kinetic, and structural RNA models.


Article Source: BIO SPACE

Related Posts

See All